Kronos Bio Inc - ESG Rating & Company Profile powered by AI
If you are employed by Kronos Bio Inc and you would like to use your ESG rating, please contact us. This webpage is a zero-cost E,S&G assessment for Kronos Bio Inc. The analysis of Kronos Bio Inc incorporates intelligence from across the web as well as from public documents by Kronos Bio Inc.
Kronos Bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 4.0, social score of 1.6 and governance score of 3.2.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | Kronos Bio Inc | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kronos Bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kronos Bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Kronos Bio Inc report the average age of the workforce?
Sign up for free to unlockDoes Kronos Bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kronos Bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kronos Bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Kronos Bio Inc offer flexible work?
Sign up for free to unlockDoes Kronos Bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kronos Bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kronos Bio Inc conduct supply chain audits?
Sign up for free to unlockDoes Kronos Bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kronos Bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kronos Bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kronos Bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kronos Bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kronos Bio Inc disclose water use targets?
Sign up for free to unlockDoes Kronos Bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Kronos Bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Kronos Bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Kronos Bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kronos Bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kronos Bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Kronos Bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kronos Bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kronos Bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kronos Bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kronos Bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kronos Bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kronos Bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Kronos Bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kronos Bio Inc disclose its waste policy?
Sign up for free to unlockDoes Kronos Bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Kronos Bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kronos Bio Inc disclose energy use targets?
Sign up for free to unlockDoes Kronos Bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kronos Bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kronos Bio Inc
These potential risks are based on the size, segment and geographies of the company.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.